Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. develops precision oncology therapies for cancers driven by the RAS/MAPK pathway. News on ERAS commonly centers on its RAS-targeting pipeline, including ERAS-0015, an investigational oral pan-RAS molecular glue evaluated in RAS-mutant solid tumors, and ERAS-4001, an oral pan-KRAS inhibitor for KRAS-mutant solid tumors.
Company updates frequently cover Phase 1 clinical data, dose-escalation results, trial collaborations and supply agreements, intellectual-property protection, development rights, public offering activity, financial results, and healthcare conference presentations. Recurring cancer settings in company disclosures include non-small cell lung cancer, pancreatic adenocarcinoma, colorectal cancer, and other RAS-mutant solid tumors.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The event will take place at the Lotte New York Palace in New York.
The company's management will conduct a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will engage in one-on-one investor meetings. Interested parties can access a live audio webcast of the presentation through Erasca.com/events, where an archived replay will remain available for 30 days following the event.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will be held at the Westin St. Francis Hotel in San Francisco, California.
The company's management will deliver a presentation on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will engage in one-on-one meetings with investors. The presentation will be accessible via a live audio webcast on Erasca.com/events, with a replay available for 30 days following the event.
Erasca specializes in discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Erasca (ERAS) reported Q3 2024 financial results and business updates, highlighting positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort. The company maintains a strong financial position with $463.3 million in cash and equivalents as of September 30, 2024, expected to fund operations into H1 2027. Q3 net loss was $31.2 million ($0.11 per share). R&D expenses increased to $27.6 million, while G&A expenses were $9.6 million. The company is advancing its RAS targeting franchise with planned IND submissions for ERAS-4001 in Q1 2025 and ERAS-0015 in H1 2025.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announces its participation in three upcoming investor conferences. The company will present at the Guggenheim Securities Healthcare Innovation Conference in Boston (November 12), the Jefferies London Healthcare Conference (November 20), and the 7th Annual Evercore HealthCONx Conference in Coral Gables (December 4). Management will engage in one-on-one investor meetings, and live audio webcasts will be available on Erasca.com/events, with replays accessible for 90 days.
Erasca (ERAS) reported positive preliminary Phase 1b SEACRAFT-1 trial data for naporafenib plus trametinib in NRASm melanoma, showing a 40% response rate (4/10 patients). The Phase 3 SEACRAFT-2 trial is progressing with randomized data expected in 2025, supported by US and European regulatory alignment for potential approval. The company's RAS targeting franchise, including pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001, remains on track for IND submissions in H1 2025 and Q1 2025, respectively. The treatment demonstrated favorable tolerability with mostly low-grade adverse events, and improved management of dermatological toxicities through mandatory primary prophylaxis.
Erasca, Inc. (Nasdaq: ERAS) announced an upcoming oral presentation of preliminary SEACRAFT-1 Phase 1 data for naporafenib plus trametinib in patients with RAS Q61X mutant solid tumors at the 36th EORTC-NCI-AACR Symposium. Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor. The presentation, scheduled for October 24, 2024, will be given by Dr. Elisa Fontana from Sarah Cannon Research Institute, London.
Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma, where favorable survival was previously demonstrated. The company will host a virtual R&D update for investors on October 24, 2024, at 8:30 AM ET, coinciding with the symposium.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, has announced its participation in two major investor conferences in September 2024. The company will present at the 22nd Annual Morgan Stanley Global Healthcare Conference on September 5 and the 2024 Cantor Global Healthcare Conference on September 18, both in New York City.
At both events, Erasca's management will engage in fireside chats and one-on-one investor meetings. The Morgan Stanley conference presentation is scheduled for 12:20 - 12:55 pm ET, while the Cantor conference slot is 3:40 - 4:10 pm ET. Live audio webcasts of these events will be available on Erasca's website, with archived replays accessible for 30 days post-event.
Erasca (ERAS) reported Q2 2024 financial results and business updates. Key highlights include:
- In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001
- Initiated SEACRAFT-2 registrational trial for naporafenib in NRASm melanoma
- Cash position of $460.2 million as of June 30, 2024, expected to fund operations into H1 2027
- Completed $229 million in equity financings
- Q2 2024 net loss of $63.2 million, or $(0.29) per share
- R&D expenses increased to $33.0 million, G&A expenses rose to $12.3 million
The company anticipates key milestones in 2024-2026, including data readouts from SEACRAFT-1, SEACRAFT-2, AURORAS-1, and BOREALIS-1 trials.
Erasca has initiated the SEACRAFT-2 Phase 3 trial for the pan-RAF inhibitor naporafenib paired with the MEK inhibitor trametinib in patients with NRAS-mutant melanoma. This pivotal trial aims to address the significant unmet need in treating this aggressive cancer type, which currently lacks approved targeted therapies.
The SEACRAFT-2 trial, designed with two stages, will first offer a randomized data readout in 2025 comparing the combination therapy against trametinib alone to determine the optimal dosage. Stage 2 aims for regulatory approval based on progression-free survival (PFS) and overall survival (OS) metrics, comparing against chemotherapy or single-agent MEK inhibitors.
Previous trials have shown promising results, with median overall survival (mOS) of up to 14.1 months and median progression-free survival (mPFS) of up to 5.1 months for patients dosed with naporafenib and trametinib, surpassing historical benchmarks.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, announced participation in two upcoming investor conferences in June 2024. Dr. Jonathan E. Lim, chairman, CEO, and co-founder, along with Dr. David M. Chacko, CFO and chief business officer, will present at the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. The Jefferies conference will be held on June 5-6 at the Marriott Marquis in New York, with the presentation scheduled for June 6 from 10:30 to 10:55 AM ET. The Goldman Sachs conference will occur from June 10-13 at the Loews Miami Beach Hotel, with a fireside chat on June 12 from 10:40 to 11:15 AM ET. Both events will be webcasted live, with replays available for 30 days on Erasca's website.